Company Overview - INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics [1][4] - The company will begin trading under the new Nasdaq ticker symbol "IVF" on April 28, 2025, reflecting its concentration on the fertility care market [1][3] Strategic Focus - The company has made a strategic decision to separate its fertility and oncology businesses into distinct operations [2] - CEO Steve Shum emphasized the focus on building, acquiring, and operating fertility clinics in the U.S. and on innovative reproductive services and technologies [3] Product and Services - INVO Fertility's principal commercial strategy includes the operation of "INVO Centers" that primarily offer the intravaginal culture (IVC) procedure enabled by the INVOcell medical device [4] - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more natural and affordable experience compared to traditional ART treatments [4] - The IVC procedure is believed to deliver comparable results at a fraction of the cost of traditional IVF and is more effective than intrauterine insemination (IUI) [4]
INVO Fertility Confirms New Nasdaq Trading Symbol of "IVF"